Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi, Andrew E. Moran, Pamela G. Coxson, et al.
JAMA (2016) Vol. 316, Iss. 7, pp. 743-743
Open Access | Times Cited: 336

Showing 1-25 of 336 citing articles:

Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Emelia J. Benjamin, Paul Muntner, Álvaro Alonso, et al.
Circulation (2019) Vol. 139, Iss. 10
Open Access | Times Cited: 8034
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Circulation (2019) Vol. 139, Iss. 25
Open Access | Times Cited: 5499
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Journal of the American College of Cardiology (2018) Vol. 73, Iss. 24, pp. e285-e350
Open Access | Times Cited: 2116
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing
Qiang Cheng, Tuo Wei, Lukas Farbiak, et al.
Nature Nanotechnology (2020) Vol. 15, Iss. 4, pp. 313-320
Open Access | Times Cited: 1492
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Journal of the American College of Cardiology (2018) Vol. 73, Iss. 24, pp. 3168-3209
Open Access | Times Cited: 1365
American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit, et al.
Endocrine Practice (2017) Vol. 23, pp. 1-87
Closed Access | Times Cited: 988
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy, Neil J. Stone, Alison Bailey, et al.
Circulation (2019) Vol. 139, Iss. 25
Open Access | Times Cited: 700
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 597
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd‐Jones, Pamela B. Morris, Christie M. Ballantyne, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 14, pp. 1366-1418
Open Access | Times Cited: 305
PCSK9 inhibitors: clinical evidence and implementation
Marc S. Sabatine
Nature Reviews Cardiology (2018) Vol. 16, Iss. 3, pp. 155-165
Closed Access | Times Cited: 300
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment
Shipra Agrawal, Joshua J. Zaritsky, Alessia Fornoni, et al.
Nature Reviews Nephrology (2017) Vol. 14, Iss. 1, pp. 57-70
Open Access | Times Cited: 269
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 224
The Evolving Future of PCSK9 Inhibitors
Robert S. Rosenson, Robert A. Hegele, Sergio Fazio, et al.
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 3, pp. 314-329
Open Access | Times Cited: 216
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Ulf Landmesser, M. John Chapman, Jane K. Stock, et al.
European Heart Journal (2017) Vol. 39, Iss. 14, pp. 1131-1143
Open Access | Times Cited: 198
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
Dhruv S. Kazi, Brandon K. Bellows, Suzanne J. Baron, et al.
Circulation (2020) Vol. 141, Iss. 15, pp. 1214-1224
Open Access | Times Cited: 192
Reactive-oxygen-species-scavenging nanomaterials for resolving inflammation
Xue Huang, Dongyang He, Zheng Pan, et al.
Materials Today Bio (2021) Vol. 11, pp. 100124-100124
Open Access | Times Cited: 123
Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association
Dhruv S. Kazi, Mitchell S.V. Elkind, Anne Deutsch, et al.
Circulation (2024) Vol. 150, Iss. 4
Closed Access | Times Cited: 55
World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
Liliana Laranjo, Fernando Laņas, Marie Chan Sun, et al.
Global Heart (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 35
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations
James A. Diao, Ivy Shi, Venkatesh L. Murthy, et al.
JAMA (2024) Vol. 332, Iss. 12, pp. 989-989
Closed Access | Times Cited: 27
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
Dhruv S. Kazi, Joanne Penko, Pamela G. Coxson, et al.
JAMA (2017) Vol. 318, Iss. 8, pp. 748-748
Open Access | Times Cited: 138
Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults
Rita Hamad, Joanne Penko, Dhruv S. Kazi, et al.
JAMA Cardiology (2020) Vol. 5, Iss. 8, pp. 899-899
Open Access | Times Cited: 133
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
Gregg C. Fonarow, Anthony Keech, Terje R. Pedersen, et al.
JAMA Cardiology (2017) Vol. 2, Iss. 10, pp. 1069-1069
Open Access | Times Cited: 129
Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study
Dariush Mozaffarian, Junxiu Liu, Stephen Sy, et al.
PLoS Medicine (2018) Vol. 15, Iss. 10, pp. e1002661-e1002661
Open Access | Times Cited: 123
Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
Ann Marie Návar, Benjamin Taylor, Hillary Mulder, et al.
JAMA Cardiology (2017) Vol. 2, Iss. 11, pp. 1217-1217
Open Access | Times Cited: 119
Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study
Yujin Lee, Dariush Mozaffarian, Stephen Sy, et al.
PLoS Medicine (2019) Vol. 16, Iss. 3, pp. e1002761-e1002761
Open Access | Times Cited: 117
Page 1 - Next Page

Scroll to top